Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

0.3901
-0.0061-1.54%
Volume:11.27K
Turnover:4.41K
Market Cap:7.28M
PE:-0.65
High:0.3950
Open:0.3845
Low:0.3820
Close:0.3962
52wk High:2.31
52wk Low:0.3641
Shares:18.65M
Float Shares:15.47M
Volume Ratio:0.20
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5992
EPS(LYR):-0.8255
ROE:-178.46%
ROA:-106.58%
PB:1.53
PE(LYR):-0.47

Loading ...

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 Sync™ Neurostimulation Console in Alzheimer’s Disease Program

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Inc: Intends to Incorporate FDA's Feedback From Q-Sub Meeting Into Its Final Pilot Study Protocol

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Hosts Live Investor Webinar Showcasing Mental Health Innovations

Reuters
·
Dec 02, 2025

Nuix (ASX:NXL) delivers shareholders solid 39% CAGR over 3 years, surging 12% in the last week alone

Simply Wall St.
·
Nov 29, 2025

Morgan Stanley Sticks to Their Buy Rating for Nuix Ltd. (NXL)

TIPRANKS
·
Nov 20, 2025

Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders

Reuters
·
Nov 18, 2025

Nexalin Technology Faces Financial Risks Amid U.S.-China Trade Tensions

TIPRANKS
·
Nov 15, 2025

Nexalin Technology Secures Exclusive Distribution Agreement With Carmi Masha in Israel

Reuters
·
Nov 13, 2025

Nuix Limited (ASX:NXL) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Simply Wall St.
·
Nov 08, 2025

BRIEF-Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by US FDA for the Treatment of Alzheimer’s Disease and Dementia

Reuters
·
Nov 05, 2025

Nexalin Technology Wins Israeli Approval for Gen-2 SYNC Neurostimulation Device

Reuters
·
Oct 30, 2025

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 Sync, 15 Ma Neurostimulation Difs™ Device in Israel

THOMSON REUTERS
·
Oct 30, 2025

Nuix (ASX:NXL) Valuation in Focus Following CEO Transition and Strategic Leadership Changes

Simply Wall St.
·
Oct 29, 2025

Nexalin announces three studies published on Gen-2 Nexalin DIFS technology

TIPRANKS
·
Oct 21, 2025

Nexalin's Difs™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia

THOMSON REUTERS
·
Oct 21, 2025

Nexalin’s Difs™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies

THOMSON REUTERS
·
Oct 21, 2025

Nexalin DIFS Neurostimulation Shows Cognitive Gains in Alzheimer’s Clinical Trials

Reuters
·
Oct 21, 2025

BRIEF-Nexalin Technology enters second amendment to equity distribution agreement - SEC filing

Reuters
·
Oct 16, 2025

Nexalin Technology Inc - Enters Amendment No. 2 to Equity Distribution Agreement - SEC Filing

THOMSON REUTERS
·
Oct 16, 2025

How Investors May Respond To Nuix (ASX:NXL) Integrating AI and Shifting to SaaS Model

Simply Wall St.
·
Oct 12, 2025